1. Home
  2. MBIO vs ONCO Comparison

MBIO vs ONCO Comparison

Compare MBIO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • ONCO
  • Stock Information
  • Founded
  • MBIO 2015
  • ONCO 2018
  • Country
  • MBIO United States
  • ONCO United States
  • Employees
  • MBIO N/A
  • ONCO N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • ONCO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBIO Health Care
  • ONCO Health Care
  • Exchange
  • MBIO Nasdaq
  • ONCO Nasdaq
  • Market Cap
  • MBIO 7.3M
  • ONCO 9.4M
  • IPO Year
  • MBIO N/A
  • ONCO 2022
  • Fundamental
  • Price
  • MBIO $2.79
  • ONCO $0.61
  • Analyst Decision
  • MBIO Strong Buy
  • ONCO
  • Analyst Count
  • MBIO 1
  • ONCO 0
  • Target Price
  • MBIO $100.00
  • ONCO N/A
  • AVG Volume (30 Days)
  • MBIO 411.9K
  • ONCO 10.4M
  • Earning Date
  • MBIO 03-10-2025
  • ONCO 12-10-2024
  • Dividend Yield
  • MBIO N/A
  • ONCO N/A
  • EPS Growth
  • MBIO N/A
  • ONCO N/A
  • EPS
  • MBIO N/A
  • ONCO N/A
  • Revenue
  • MBIO N/A
  • ONCO $1,870,605.00
  • Revenue This Year
  • MBIO N/A
  • ONCO N/A
  • Revenue Next Year
  • MBIO N/A
  • ONCO N/A
  • P/E Ratio
  • MBIO N/A
  • ONCO N/A
  • Revenue Growth
  • MBIO N/A
  • ONCO N/A
  • 52 Week Low
  • MBIO $2.71
  • ONCO $0.32
  • 52 Week High
  • MBIO $74.50
  • ONCO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 28.00
  • ONCO 47.03
  • Support Level
  • MBIO $3.96
  • ONCO $0.58
  • Resistance Level
  • MBIO $6.70
  • ONCO $0.70
  • Average True Range (ATR)
  • MBIO 0.97
  • ONCO 0.10
  • MACD
  • MBIO -0.12
  • ONCO 0.02
  • Stochastic Oscillator
  • MBIO 2.83
  • ONCO 25.62

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: